Turku, Finland, March 3rd, 2021 – Forendo Pharma, a clinical-stage drug development company focusing on novel treatments in women's health, today announced the completion of Phase 1 studies in healthy volunteers for its lead development program in endometriosis, FOR-6219, and provided a development outlook. The successfully concluded Phase 1 program demonstrated that FOR-6219, a HSD17B1 enzymetargeting small-molecule, was safe and well-tolerated and delivered additional results supporting Forendo's therapeutic concept.